Clinical trial registry record

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 10, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04270669
Last registry update
January 10, 2022
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
RemeGen Co., Ltd.
Enrollment
37
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
37
Population
ALL · 50 Years to 80 Years
Duration
2020-04-15 to 2021-10-29
Intervention
intravitreal injection of RC28-E 0.5mg; intravitreal injection of RC28-E 1.0mg; intravitreal injection of RC28-E2.0mg
Comparator
Not reported
Outcomes measured
Mean change of BCVA from baseline at 12 week; — Baseline, Week 12; Mean change of BCVA from baseline at 48 week; — Baseline, Week 48; Incidence and severity of AEs — Baseline up to Week 48; The pharmacokinetic (PK) characteristics of RC28-E; — Baseline up to Week 48; Frequency of administration RC28-E within 48 weeks; — Baseline up to Week 48; Mean change of BCVA from baseline at Protocol Specified Time-Points. — Baseline up to Week 48
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON